Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis^*

References

• Health Canada. Diabetes in Canada, 2nd Edition. Health Canada 2002. Available at: URL: http://www.phac.aspc.gc.ca/publicat/dic-dac2/pdf/dic-dac2_en.pdf
   Google Scholar
• Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. Br Med J 2001;322:1389-93
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• The UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association. 2003 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27:i-S140
   Google Scholar
• Hirsh IB. Insulin analogues. N Engl J Med 2005;352:174-83
   PubMed Web of Science ®Google Scholar
• Hauber A, Gale EAM. The market in diabetes. Diabetologia 2006;49:247-52
   PubMed Web of Science ®Google Scholar
• Current Utilization of Insulin Products in Canada. Current Utilization and Practice Analysis. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), 2008
   Google Scholar
• An Economic Evaluation of Insulin Analogues for the Treatment of Patients with Type 1 and Type 2 Diabetes Mellitus in Canada. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS);2008
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004;20:1729-46
   PubMed Web of Science ®Google Scholar
• Valentine W, Palmer AJ, Erney-Albrecht KM, et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther 2006;23:191-207
   PubMed Web of Science ®Google Scholar
• Brixner DI, McAdam-Marx C. Cost-effectiveness of insulin analogs. Am J Manage Care 2008;14:766-75
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Curr Med Res Opin 2004;20:S67-73
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CLI, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2008;22:1523-34
   Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes - Insulin Glargine. 2002 Jan 12. Technology Appraisal Guidance - No. 53
   Google Scholar
• Rosenstock J, Davies M, Home PD, et al. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 2008;51:408-16
   PubMed Web of Science ®Google Scholar
• Fritsche A, Haring H. At last, a weight neutral insulin. Int J Obes 2004;28:S41-46
   PubMed Web of Science ®Google Scholar
• Bartley P, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabetic Med 2008;25:442-9
   PubMed Web of Science ®Google Scholar
• Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared to NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7
   PubMed Web of Science ®Google Scholar
• Meneghini L, Koenen C, Weng W, Selam J-L. The usage of a simplified self-titration dosing guideline (303 algorithm) for insulin detemir in patients with type 2 diabetes -- results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab 2007;9:902-13
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Consensus PanelGuidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:27-40
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Visible Minority Population, by Age Group (2001 Census). Statistics Canada, 2005
   Google Scholar
• Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey (NHANES). U.S. Department of Health and Human Services 2000
   Google Scholar
• O'Reilly D, Hopkins R, Blackhouse G, et al. Development of an Ontario Diabetes Economic Model (ODEM) and Application to a Multidisciplinary Primary Care Diabetes Management Program. Hamilton, Ontario, Canada: Program for Assessment of Technology in Health (PATH), 2006
   Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2-9N
   PubMed Web of Science ®Google Scholar
• Phillips SJ, Whisnant JP, O'Fallon WM, et al. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-59
   PubMed Web of Science ®Google Scholar
• Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-16
   PubMed Web of Science ®Google Scholar
• Brändle M, Zhou H, Smith BR et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4
   PubMed Web of Science ®Google Scholar
• Nova Scotia Pharmacy: Annual Pricing, 2007
   Google Scholar
• Nova Scotia Pharmacy: Pricing with a 30-day Supply Assumption, 2007
   Google Scholar
• Nova Scotia. Nova Scotia Optometrist Fees. Nova Scotia, 2007
   Google Scholar
• Nova Scotia. Nova Scotia Podiatrist Fees. Nova Scotia, 2007
   Google Scholar
• Coyle D, Palmer A, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2003;20:31-42
   Web of Science ®Google Scholar
• O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3:7
   PubMed Web of Science ®Google Scholar
• Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005;21:1617-29
   PubMed Web of Science ®Google Scholar
• Alberta Physician Fee Schedule. Alberta Physician Fee Schedule. Province of Alberta, Ministry of Health 2004. Available at: URL: http://www.web.ab.ca/pdfs/providers/WCB_Fee_Schedule_Alberta_Physicians.pdf
   Google Scholar
• Manns B, Johnson JA, Taub K et al. Quality of life in patients with end-stage renal disease over time: the impact of dialysis modality and other important determinants. Edmonton, Alberta, Canada: Institute of Pharmaco-Economics, 2002. Report No. 02-05
   Google Scholar
• Manns B, Tonelli M, Shrive F et al. Sevelamer in patients with end-stage renal disease: a systematic review and economic evaluation. Canadian Agency for Drugs and Technologies in Health, 2006
   Google Scholar
• Health Costing in Alberta: 2006 Annual Report. Edmonton, Alberta, Canada: Alberta Health and Wellness, 2008
   Google Scholar
• Caro J, Migliaccio-Walle K, Ishak KJ, et al. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord 2005;5:14
   PubMedGoogle Scholar
• Royal Bank of Canada, 2007. Bank of Canada, Inflation Calculator, 2008. Available at: URL: http://www.bankofcanada.ca/en/rates/inflation_calc.html
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd edn. Ottawa, Ontario, Canada: CADTH Publications, 2006
   Google Scholar
• Halpern EF, Weinstein MC, Hunink MG, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Dec Making 2000;20:314-22
   PubMed Web of Science ®Google Scholar
• Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81
   Google Scholar
• Leiter LA, Yale J-F, Chaisson J-L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-92
   Google Scholar
• Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008;24:87-92
   PubMed Web of Science ®Google Scholar
• Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycaemia in diabetes: implications for diabetes management and patient education. Patient Educ Counsel 2007;68:10-15
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study GroupEffects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative GroupIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Diabetes Care 2009;32:187-92
   PubMed Web of Science ®Google Scholar